Cannabinol (CBN) showed anti-inflammatory effects in skin cells through a TRPV1 receptor mechanism

CBN increased CB1 gene expression and TRPV1 protein expression and function in keratinocytes. It modulated anandamide and 2-AG metabolism. In inflamed cells, CBN reduced pro-inflammatory IL-8, IL-12, and IL-31 while increasing anti-inflammatory IL-10. The reduction of IL-31 was specifically mediated by TRPV1. CBN also modulated GSK3-beta through the MAPK signaling pathway.

Human keratinocytes (HaCaT cells) were treated with CBN in both normal and LPS-inflamed conditions. Researchers measured expression and function of cannabinoid receptors (CB1, CB2) and TRPV1, endocannabinoid metabolic enzyme activities (NAPE-PLD, FAAH, MAGL), cytokine release (IL-8, IL-10, IL-12, IL-31), and MAPK signaling pathway components.

CBN is gaining consumer interest as a cannabis minor cannabinoid, but its mechanisms are poorly understood. This study reveals a specific pathway (TRPV1-mediated IL-31 reduction) through which CBN exerts anti-inflammatory effects on skin, providing scientific support for its potential in dermatological applications.

IL-31 is a key itch-inducing cytokine in inflammatory skin conditions like eczema and atopic dermatitis. The finding that CBN reduces IL-31 through TRPV1 provides a specific mechanistic rationale for CBN in anti-itch skincare products, moving beyond general "anti-inflammatory" claims.

In vitro study using an immortalized cell line (HaCaT), which may not fully represent in vivo skin biology. Single cannabinoid tested in isolation, whereas real cannabis products contain multiple compounds. Concentrations used may not reflect achievable tissue levels from topical application.